Patent · US Active

Multi-clade chimeric immunogens derived from highly conserved regions of the human immunodeficiency virus type 1 (HIV-1) consensus proteome

US7981430B2 · kind B2 · utility

10Cited by
0References
2Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 23, 2007
Grant dateJul 19, 2011
Priority date
Expiry dateApr 17, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/16071
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, such as Gag, Pol, Vif, and Env proteins, which are partial sequences. HIVCON is an AFP in which the HIV domains are from several HIV clade consensus sequences and which optionally contains additional domains which may be useful, for example, in monitoring expression levels or laboratory animal immune responses. Other aspects of the invention may include compositions and methods for inducing an anti-HIV immune response in a subject, preferably with a DNA prime-MVA boost strategy, and to induce a cell-mediated immune response.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.